Anna M. Wu
-
- Monoclonal and Polyclonal Antibodies Research 95
- Radiopharmaceutical Chemistry and Applications 89
- Oncology top 0.5%
- CAR-T cell therapy research 24
- HER2/EGFR in Cancer Research 17
- Materials Chemistry top 0.5%
- Molecular Biology top 0.5%
- Glycosylation and Glycoproteins Research 20
- Biomaterials top 0.5%
-
- Prostate Cancer Treatment and Research 18
-
- Lymphoma Diagnosis and Treatment 17
-
- Immunotherapy and Immune Responses 17
- Co-authors
- Sanjiv S. GambhirGobalakrishnan SundaresanShimon WeissLaurent A. BentolilaJames M. TsayXavier MichaletSören DooseFabien Pinaud
- Journals
- Journal of Nuclear Medicine (13 papers)Molecular Imaging and Biology (11 papers)Protein Engineering Design and Selection (9 papers)
- Partner nations
- United StatesChinaSweden
In The Last Decade
Anna M. Wu
215 papers receiving 17.2k citations
Hit Papers
Peers
Comparison fields: 5 of 166
- Radiology, Nuclear Medicine and Imaging 5.4k
- Oncology 3.7k
- Materials Chemistry 5.0k
- Molecular Biology 7.0k
- Biomaterials 1.1k
Countries citing papers authored by Anna M. Wu
This map shows the geographic impact of Anna M. Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna M. Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna M. Wu more than expected).
Fields of papers citing papers by Anna M. Wu
This network shows the impact of papers produced by Anna M. Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna M. Wu. The network helps show where Anna M. Wu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Anna M. Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 29 | |
| 2 | 2023 | 3 | |
| 3 | 2022 | 3 | |
| 4 | 2022 | 9 | |
| 5 | 2021 | 19 | |
| 6 | 2021 | 62 | |
| 7 | 2020 | 11 | |
| 8 | 2020 | 10 | |
| 9 | 2018 | 26 | |
| 10 | 2018 | 68 | |
| 11 | 2018 | 37 | |
| 12 | 2017 | 38 | |
| 13 | 2017 | 120 | |
| 14 | Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppressionbreakdown → | 2017 | 399 |
| 15 | 2015 | 237 | |
| 16 | 2015 | 41 | |
| 17 | 2014 | 24 | |
| 18 | 2014 | 25 | |
| 19 | 2006 | 54 | |
| 20 | Leu-9 (CD 7) positivity in acute leukemias: a marker of T-cell lineage? | 1987 | 7 |
About Anna M. Wu
Anna M. Wu is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Molecular Biology and Pathology and Forensic Medicine, having authored 217 papers that have together received 17.7k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (95 papers), Radiopharmaceutical Chemistry and Applications (89 papers), CAR-T cell therapy research (24 papers), Glycosylation and Glycoproteins Research (20 papers), Prostate Cancer Treatment and Research (18 papers), Lymphoma Diagnosis and Treatment (17 papers), Immunotherapy and Immune Responses (17 papers) and HER2/EGFR in Cancer Research (17 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (5.4k citations), Oncology (3.7k citations), Materials Chemistry (5.0k citations), Molecular Biology (7.0k citations) and Biomaterials (1.1k citations). Anna M. Wu has collaborated with scholars based in United States, China and Sweden. Frequent co-authors include Sanjiv S. Gambhir, Gobalakrishnan Sundaresan, Shimon Weiss, Laurent A. Bentolila, James M. Tsay, Xavier Michalet, Sören Doose, Fabien Pinaud, Peter D. Senter and Tove Olafsen. Their work appears in journals such as Journal of Nuclear Medicine, Molecular Imaging and Biology, Protein Engineering Design and Selection, Cancer Biotherapy and Radiopharmaceuticals and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.